Wedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY)

Inozyme Pharma (NASDAQ:INZY - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at Wedbush in a report released on Monday, RTT News reports. They currently have a $15.00 target price on the stock. Wedbush's price objective suggests a potential upside of 155.54% from the company's previous close.

Separately, HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Inozyme Pharma in a research report on Wednesday, March 13th.

Inozyme Pharma Trading Down 8.4 %

Shares of INZY stock traded down $0.54 on Monday, hitting $5.87. The company had a trading volume of 1,843,762 shares, compared to its average volume of 585,646. The firm has a market cap of $362.59 million, a P/E ratio of -4.22 and a beta of 1.37. The stock's 50-day moving average is $6.07 and its two-hundred day moving average is $4.61. The company has a debt-to-equity ratio of 0.32, a quick ratio of 13.36 and a current ratio of 13.36. Inozyme Pharma has a twelve month low of $2.69 and a twelve month high of $7.80.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04). On average, equities research analysts anticipate that Inozyme Pharma will post -1.48 earnings per share for the current fiscal year.

Insider Activity at Inozyme Pharma

In other Inozyme Pharma news, CEO Douglas A. Treco sold 7,523 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now directly owns 20,665 shares of the company's stock, valued at $143,415.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.88% of the stock is currently owned by company insiders.

Institutional Trading of Inozyme Pharma

Large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its holdings in shares of Inozyme Pharma by 134.4% in the third quarter. Tower Research Capital LLC TRC now owns 8,332 shares of the company's stock worth $35,000 after acquiring an additional 4,777 shares during the period. Two Sigma Investments LP bought a new position in shares of Inozyme Pharma in the third quarter worth $35,000. Strs Ohio bought a new position in shares of Inozyme Pharma in the third quarter worth $41,000. PDT Partners LLC bought a new position in shares of Inozyme Pharma in the first quarter worth $42,000. Finally, Renaissance Technologies LLC bought a new position in shares of Inozyme Pharma in the first quarter worth $49,000. 88.30% of the stock is owned by hedge funds and other institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.